诺和龙是类似于磺脲类又优于磺脲类的抗糖尿病的药物,它是诺和诺德公司新开发的抗糖尿病新药。 诺和龙和磺脲类药物一样能够促进胰岛β细胞分泌胰岛素,都是作用于β细胞膜的ATP敏感生钾通而增加胰岛素的分泌,所不同的是诺和龙是增加胰岛素分泌的幅度(峰值增加)、磺脲类是增加胰岛素分泌的频率(次数增加),因此诺和龙虽然增加胰岛素的分泌量但并不增加胰岛素细胞的负担而磺脲类药物则会加重胰岛细胞的负担;另一方面,诺和龙的安全性也比较好,低血糖的发生率低,一般不加重肝肾功能的负担。 诺和龙的服药时间和拜糖平相似即餐时服,也可于餐前15分钟服药。由于它有其独特的优点,所以该药较贵,每片(0.5mg)约2.7～3.0元。 Novozymes are anti-diabetic drugs similar to sulfonylureas and sulfonylureas, which is a new anti-diabetic drug developed by Novo Nordisk. Connaught and dragons and sulfonylureas can promote pancreatic β-cell insulin secretion, are acting on the beta-cell membrane of the ATP-sensitive potassium generation and increase the secretion of insulin, Connaught is the dragon is to increase the magnitude of insulin secretion (peak Increase), sulfonylurea is to increase the frequency of insulin secretion (increased frequency), so Novozymes while increasing insulin secretion but does not increase the burden on insulin cells and sulfonylurea drugs will exacerbate the burden of islet cells; the other In terms of Novo Nordisk’s safety is also relatively good, the incidence of hypoglycemia is low, generally do not increase the burden of liver and kidney function. Connaught and dragons medication time and thanks to the sugar level is similar mealtime service, but also in 15 minutes before meals medication. Because of its unique advantages, the drug is more expensive, each tablet (0.5mg) about 2.7 to 3.0 yuan.